

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 20, 2005
(Date of earliest event reported)

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

(State or other jurisdiction
of Incorporation)

1-11353

(Commission
File Number)

13-3757370

(I.R.S. Employer
Identification No.)

**358 SOUTH MAIN STREET,
BURLINGTON, NORTH CAROLINA**

(Address of principal executive offices)

27215

(Zip Code)

336-229-1127

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company dated October 20, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings
(Registrant)

Date: October 20, 2005


By: /s/Bradford T. Smith
Bradford T. Smith, Executive Vice President
and Secretary



This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2004, and subsequent filings.



The Clinical Laboratory Testing Market - \$40 billion Annually




- Independent clinical lab share is \$16 billion
- Represents 2% to 3% of all health care spending
- Influences /directs approximately 80% of health care spending
- Rapidly evolving technology, emphasis on preventative medicine and aging of population are all driving growth
- Has grown at a CAGR of between 5% and 6%

Source: Company estimates, industry reports and 2004 revenue for LabCorp.

Profile of LabCorp

- A leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
- Offers a broad range of routine and esoteric/genomic tests
- Conducts testing on more than 360,000 specimens daily
- Provides lab services to physicians and other health care providers
- Approximately 24,500 employees nationwide


Primary Testing Locations




LabCorp's Investment and Performance Fundamentals

- History of Strong Financial Performance
- Significant Cash Generator
- Industry leading EBITDA margins
- Strong Balance Sheet
- Investment Grade Credit Ratings

Net Sales (in millions)



EBITDA Margin



EPS



Operating Cash Flow (in millions)



(1) Includes approximately \$50 million of benefit from one-time tax credits recorded in 2003.

LabCorp's Strategy

To **lead** the industry in achieving long-term **growth and profitability** by strengthening our **nationwide core testing** business and expanding our **higher-growth, higher-value esoteric and genomic businesses.**

Strategic Focus Areas

Scientific Leadership

- Licensing/partnerships
- Cancer
- Acquisitions

Managed Care

- Reduce leakage
- Appropriate prices
- Value of new lab tests

Customer Retention

- Specimen tracking
- Report improvement
- Call center consolidation
- Customer connectivity

Third Quarter Results (in millions, except per share data)

	<u>9/30/04</u>	<u>9/30/05</u>	<u>+ / (-)</u>
Revenue	\$781.5	\$852.9	9.1%
EBITDA ⁽¹⁾	\$200.8	\$213.6	6.4%
EBITDA Margin	25.7%	25.0%	(70 bp)
Diluted EPS ⁽²⁾	\$0.63	\$0.70	11.1%

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 3rd quarter 2005 earnings release furnished on Form 8-K on October 20, 2005.

(2) Excluding \$0.04 per diluted share impact of restructuring and other special charges in third quarter of 2005.

Nine-Month Results (in millions, except per share data)

	<u>9/30/04</u>	<u>9/30/05</u>	<u>+ / (-)</u>
Revenue	\$2,318.3	\$2,505.3	8.1%
EBITDA ⁽¹⁾	\$602.8	\$646.3	7.2%
EBITDA Margin	26.0%	25.8%	(20 bp)
Diluted EPS ⁽²⁾	\$1.87	\$2.14	14.4%

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 3rd quarter 2005 earnings release furnished on Form 8-K on October 20, 2005.

(2) Excluding the \$0.07 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss.

2005 Nine-Month Financial Achievements

- Diluted EPS of \$2.14 ⁽¹⁾
- EBITDA margin of 25.8% of sales
- Operating cash flow of \$413.0 million
- Increased revenues 8.1% (1.2% volume; 6.9% price)
- Repurchased approximately \$201 million of LabCorp stock
- Completed US LABS and Esoterix acquisitions

(1) Excluding the \$0.07 per diluted share impact of restructuring and other special charges, and a non-recurring investment loss.

Price & Volumes: Trends by Payor Type

Financial Performance

	2003		2004		YTD 2005	
	PPA \$	Accessions millions	PPA \$	Accessions millions	PPA \$	Accessions millions
Client (Physicians)	\$27.07	31.7	\$26.61	32.7	\$29.03	24.2
Patient	118.48	2.5	123.59	2.5	134.08	1.7
Third Party (MC/MD/Insurance)	34.25	18.1	34.84	18.9	38.52	14.8
Managed Care						
• Capitated	9.95	12.9	10.36	12.8	10.42	9.8
• Fee for service	45.68	22.7	46.01	24.2	47.10	19.1
Total	32.74	35.6	33.67	37.0	34.64	28.9
LabCorp Total	\$33.43	87.9	\$33.86	91.1	\$35.99	69.6

Financial Performance

Revenue Analysis by Business Area

	YTD SEP 2004				YTD SEP 2005				05 vs 04
	Revenue \$Million	Accns 000	% Accns to total	PPA \$	Revenue \$Million	Accns 000	% Accns to total	PPA \$	PPA Incr/(Decr)
Genomic	\$219.2	1,868.9	2.7%	\$117.30	\$247.9	2,124.5	3.1%	\$116.70	(0.5%)
Identity/Gene Probes	125.3	2,843.3	4.1%	44.06	131.9	2,933.8	4.2%	44.95	2.0%
All Genomic	344.5	4,712.2	6.8%	73.11	379.8	5,058.3	7.3%	75.09	2.7%
Other Esoteric	221.8	5,360.1	7.8%	41.38	251.3	6,046.9	8.7%	41.55	0.4%
Histology	152.7	1,690.0	2.5%	90.34	210.7	1,807.2	2.6%	116.61	29.1%
All Genomic/ Esoteric Core	719.0	11,762.3	17.1%	61.12	841.8	12,912.4	18.6%	65.19	6.7%
	1,599.3	57,059.0	82.9%	28.03	1,663.5	56,694.6	81.4%	29.34	4.7%
Total	\$2,318.3	68,821.3	100.0%	\$33.69	\$2,505.3	69,607.0	100.0%	\$35.99	6.8%

Free Cash Flow Investment Strategy

- Acquisitions
- Stock repurchase program
- Retain flexibility in utilizing remaining cash

Updated 2005 Financial Guidance

- Revenue growth of approximately 7.5% to 8% compared to 2004.
- EBITDA margins of 25.5% of revenues.
- Diluted EPS in the range of \$2.73 to \$2.77, excluding the third quarter restructuring and other special charges.
- Capital expenditures of between \$90 and \$100 million.
- Free cash flow of between \$440 and \$465 million.
- Net interest expense of approximately \$32 million.
- Bad debt rate of approximately 5.3% of sales for the remainder of the year.

Financial Guidance for 2005 (cont'd.)

- We expect the fourth quarter to be impacted by the continued effects of third quarter hurricanes. We estimate the following negative impacts:
 - Revenue - approximately \$7.5 million
 - Volume - approximately 1%
 - EPS - approximately \$0.02
- As a reminder, there is one less revenue day in the fourth quarter of 2005 versus the fourth quarter of 2004
- Guidance does not include:
 - Any potential restructuring charges at LabCorp associated with the continued integration of US LABS and Esoterix into LabCorp, or
 - Future share repurchases beyond the third quarter.

Preliminary Financial Guidance for 2006

- Revenue growth of approximately 6.5% to 7.5% percent.
- Diluted earnings per share growth of 12% to 14%, compared to LabCorp's 2005 guidance.

Other Financial Information
For the Quarter Ended September 30, 2005

(\$ in millions)	Q1	Q2	Q3	YTD 2005
Depreciation	\$ 23.2	\$ 24.1	\$ 24.2	\$ 71.5
Amortization	\$ 12.1	\$ 13.1	\$ 13.1	\$ 38.3
Capital expenditures	\$ 25.5	\$ 20.2	\$ 25.7	\$ 71.4
Cash flows from operations	\$ 154.5	\$ 86.5	\$ 172.0	\$ 413.0
Bad debt as a percentage of sales	5.5%	5.3%	5.3%	5.4%
Effective interest rate on debt:				
Zero coupon-subordinated notes	2.00%	2.00%	2.00%	2.00%
5 ½% Senior Notes (including effect of interest rate swap)	5.38%	5.38%	5.38%	5.38%
Revolving credit facility (weighted average)	3.31%	3.62%	4.34%	4.34%
Days sales outstanding	55	55	55	55



LabCorp
Laboratory Corporation of America

